BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8453588)

  • 1. Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide.
    Gururangan S; Bowman LC; Parham DM; Wilimas JA; Rao B; Pratt CB; Douglass EC
    Cancer; 1993 Apr; 71(8):2653-9. PubMed ID: 8453588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
    Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
    Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
    Al-Hader AA; Jain A; Al-Nasrallah N; Einhorn LH
    Am J Clin Oncol; 2015 Aug; 38(4):364-6. PubMed ID: 23799289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
    Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
    Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
    Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
    J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
    Le Chevalier T; Thomas F; Subirana R; Baldeyrou P; Ruffie P; Arriagada R; Chazard M; Tursz T
    Cancer; 1991 Jun; 67(12):2980-3. PubMed ID: 1646067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma.
    Lafay-Cousin L; Mabbott DJ; Halliday W; Taylor MD; Tabori U; Kamaly-Asl ID; Kulkarni AV; Bartels U; Greenberg M; Bouffet E
    J Neurosurg Pediatr; 2010 Jun; 5(6):615-21. PubMed ID: 20515336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining therapeutic strategies for patients with resistant Wilm's tumor.
    Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All children with malignant rhabdoid tumors should be treated initially with intensive chemotherapy.
    Hernández-Marqués C; Lassaletta A; Cormenzana M; García-Esparza E; Madero-López L
    Pediatr Hematol Oncol; 2015 Apr; 32(3):193-8. PubMed ID: 24852450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
    Fléchon A; Biron P; Philip I; Blay JY; Droz JP
    Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005.
    Brennan B; De Salvo GL; Orbach D; De Paoli A; Kelsey A; Mudry P; Francotte N; Van Noesel M; Bisogno G; Casanova M; Ferrari A
    Eur J Cancer; 2016 Jun; 60():69-82. PubMed ID: 27082136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
    Wong CI; Benedetti DJ; Kao PC; Ma C; Marcus KJ; Mullen EA
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30422. PubMed ID: 37218455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for brain tumors in infants and young children.
    Iwama J; Ogiwara H; Kiyotani C; Terashima K; Matsuoka K; Iwafuchi H; Morota N
    J Neurosurg Pediatr; 2015 May; 15(5):488-92. PubMed ID: 25723725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.